Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02386098




Registration number
NCT02386098
Ethics application status
Date submitted
6/03/2015
Date registered
11/03/2015
Date last updated
20/08/2018

Titles & IDs
Public title
Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults
Scientific title
A Phase 2b Randomized, Active-Controlled, Staged, Open-Label Trial to Investigate Safety and Efficacy of BMS-955176/GSK3532795 in Combination With Dolutegravir and Atazanavir (With or Without Ritonavir) in Treatment-Experienced HIV-1 Infected Adults
Secondary ID [1] 0 0
AI468-048
Secondary ID [2] 0 0
205892
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
HIV Infections 0 0
Condition category
Condition code
Infection 0 0 0 0
Acquired immune deficiency syndrome (AIDS / HIV)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BMS-955176
Treatment: Drugs - Atazanavir (ATV)
Treatment: Drugs - Ritonavir (RTV)
Treatment: Drugs - Dolutegravir (DTG)
Treatment: Drugs - Tenofovir (TDF)

Experimental: Arm 1: BMS-955176 + ATV + RTV + DTG - BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally

Other: Arm 2: TDF + ATV + RTV + DTG - TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally

Experimental: Arm 3: BMS-955176 + ATV + DTG - BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally

Experimental: Arm 4: BMS-955176 + ATV + DTG - BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally

Other: Arm 5: TDF + ATV + RTV + DTG - TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally


Treatment: Drugs: BMS-955176
HIV Maturation Inhibitor

Treatment: Drugs: Atazanavir (ATV)
Atazanavir

Treatment: Drugs: Ritonavir (RTV)
Ritonavir

Treatment: Drugs: Dolutegravir (DTG)
Dolutegravir

Treatment: Drugs: Tenofovir (TDF)
Tenofovir
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <40 Copies Per Milliliter (c/mL) at Week 24-Stage 1
Timepoint [1] 0 0
Week 24
Primary outcome [2] 0 0
Percentage of Participants With Plasma HIV-1 RNA <40 c/mL at Week 24-Stage 2
Timepoint [2] 0 0
Week 24
Secondary outcome [1] 0 0
Percentage of Participants With Plasma HIV-1 RNA <40 c/mL at Weeks 48 and 96-Stage 1
Timepoint [1] 0 0
Weeks 48 and 96
Secondary outcome [2] 0 0
Percentage of Participants With Plasma HIV-1 RNA <40 c/mL at Weeks 48 and 96-Stage 2
Timepoint [2] 0 0
Weeks 48 and 96
Secondary outcome [3] 0 0
Percentage of Participants With HIV-1 RNA <200 c/mL at Weeks 24, 48 and 96-Stage 1
Timepoint [3] 0 0
Weeks 24, 48 and 96
Secondary outcome [4] 0 0
Percentage of Participants With HIV-1 RNA <200 c/mL at Weeks 24, 48 and 96-Stage 2
Timepoint [4] 0 0
Weeks 24, 48 and 96
Secondary outcome [5] 0 0
Change From Baseline in Logarithm to the Base 10 (log10) HIV-1 RNA Over Time-Stage 1
Timepoint [5] 0 0
Baseline and up to Week 72
Secondary outcome [6] 0 0
Change From Baseline in log10 HIV-1 RNA Over Time-Stage 2
Timepoint [6] 0 0
Baseline and up to Week 96
Secondary outcome [7] 0 0
Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count Over Time-Stage 1
Timepoint [7] 0 0
Baseline and up to Week 72
Secondary outcome [8] 0 0
Change From Baseline in CD4+ Cell Count Over Time-Stage 2
Timepoint [8] 0 0
Baseline and up to Week 96
Secondary outcome [9] 0 0
Change From Baseline in Percentage of CD4+ Cells Over Time-Stage 1
Timepoint [9] 0 0
Baseline and up to Week 72
Secondary outcome [10] 0 0
Change From Baseline in Percentage of CD4+ Cells Over Time-Stage 2
Timepoint [10] 0 0
Baseline and up to Week 96
Secondary outcome [11] 0 0
Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Stage 1
Timepoint [11] 0 0
Up to Week 96
Secondary outcome [12] 0 0
Number of Participants With SAEs and AELDs-Stage 2
Timepoint [12] 0 0
Up to Week 96
Secondary outcome [13] 0 0
Number of Participants With Occurrence of New Acquired Immunodeficiency Syndrome (AIDS) Defining Events-Stage 1
Timepoint [13] 0 0
Up to Week 96
Secondary outcome [14] 0 0
Number of Participants With Occurrence of New AIDS Defining Events-Stage 2
Timepoint [14] 0 0
Up to Week 96
Secondary outcome [15] 0 0
Maximum Observed Concentration (Cmax) for BMS-955176-Stage 1
Timepoint [15] 0 0
Week 2 (pre-dose, 1, 2, 2.5, 3, 4, 4.5, 5, 6, 8, 12 hours post-dose and 24 hours [morning pre-dose])
Secondary outcome [16] 0 0
Cmax for BMS-955176-Stage 2
Timepoint [16] 0 0
Week 2 (pre-dose, 1, 2, 2.5, 3, 4, 4.5, 5, 6, 8, 12 hours post-dose and 24 hours [morning pre-dose])
Secondary outcome [17] 0 0
Time of Maximum Observed Plasma Concentration (Tmax) for BMS-955176-Stage 1
Timepoint [17] 0 0
Week 2 (pre-dose, 1, 2, 2.5, 3, 4, 4.5, 5, 6, 8, 12 hours post-dose and 24 hours [morning pre-dose])
Secondary outcome [18] 0 0
Tmax for BMS-955176-Stage 2
Timepoint [18] 0 0
Week 2 (pre-dose, 1, 2, 2.5, 3, 4, 4.5, 5, 6, 8, 12 hours post-dose and 24 hours [morning pre-dose])
Secondary outcome [19] 0 0
Observed Plasma Concentration at the End of a Dosing Interval (Ctau) for BMS-955176-Stage 1
Timepoint [19] 0 0
Week 2 (pre-dose, 1, 2, 2.5, 3, 4, 4.5, 5, 6, 8, 12 hours post-dose and 24 hours [morning pre-dose])
Secondary outcome [20] 0 0
Ctau for BMS-955176-Stage 2
Timepoint [20] 0 0
Week 2 (pre-dose, 1, 2, 2.5, 3, 4, 4.5, 5, 6, 8, 12 hours post-dose and 24 hours [morning pre-dose])
Secondary outcome [21] 0 0
Observed Pre-dose Plasma Concentration (C0) for BMS-955176-Stage 1
Timepoint [21] 0 0
Week 2 (pre-dose, 1, 2, 2.5, 3, 4, 4.5, 5, 6, 8, 12 hours post-dose and 24 hours [morning pre-dose])
Secondary outcome [22] 0 0
C0 for BMS-955176-Stage 2
Timepoint [22] 0 0
Week 2 (pre-dose, 1, 2, 2.5, 3, 4, 4.5, 5, 6, 8, 12 hours post-dose and 24 hours [morning pre-dose])
Secondary outcome [23] 0 0
Area Under the Concentration-time Curve in One Dosing Interval (AUC[Tau]) for BMS-955176-Stage 1
Timepoint [23] 0 0
Week 2 (pre-dose, 1, 2, 2.5, 3, 4, 4.5, 5, 6, 8, 12 hours post-dose and 24 hours [morning pre-dose])
Secondary outcome [24] 0 0
AUC(Tau) for BMS-955176-Stage 2
Timepoint [24] 0 0
Week 2 (pre-dose, 1, 2, 2.5, 3, 4, 4.5, 5, 6, 8, 12 hours post-dose and 24 hours [morning pre-dose])
Secondary outcome [25] 0 0
Number of Participants With Emergence of HIV Drug Resistance-Stage 1
Timepoint [25] 0 0
Up to Week 96
Secondary outcome [26] 0 0
Number of Participants With Emergence of HIV Drug Resistance-Stage 2
Timepoint [26] 0 0
Up to Week 96

Eligibility
Key inclusion criteria
* Men and non-pregnant women, at least 18 years of age
* Antiretroviral treatment-experienced, defined as having documented evidence of having failed 1 or 2 regimens that include 2 or 3 classes of antiretroviral (ARV) (with or without documented resistance)
* CD4+ T-cell count > 50 cells/mm3
* Screening genotype/phenotype indicating susceptibility to study drugs (unboosted ATV, FC < 2.2; DTG; TDF)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Antiretroviral treatment-experienced adults who have failed > 2 ARV regimens
* Resistance or partial resistance to any study drug determined by tests at Screening
* Historical or documented genotypic and/or phenotypic drug resistance testing showing certain resistance mutations to ATV, TDF, RAL, Protease Inhibitors, and certain TAMs
* Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV)
* Blood tests that indicate normal liver function
* Hemoglobin < 8.0 g/dL, Platelets < 50,000 cells/mm3

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/07/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
7/06/2017
Sample size
Target
Accrual to date
Final
86
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
GSK Investigational Site - Darlinghurst, Sydney
Recruitment hospital [2] 0 0
GSK Investigational Site - Darlinghurst
Recruitment hospital [3] 0 0
GSK Investigational Site - Sydney
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst, Sydney
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
2010 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
Oklahoma
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
Argentina
State/province [9] 0 0
Buenos Aires
Country [10] 0 0
Argentina
State/province [10] 0 0
Santa Fe
Country [11] 0 0
Argentina
State/province [11] 0 0
Córdoba
Country [12] 0 0
Argentina
State/province [12] 0 0
Mar del Plata
Country [13] 0 0
Canada
State/province [13] 0 0
British Columbia
Country [14] 0 0
Canada
State/province [14] 0 0
Manitoba
Country [15] 0 0
Canada
State/province [15] 0 0
Ontario
Country [16] 0 0
Canada
State/province [16] 0 0
Quebec
Country [17] 0 0
Chile
State/province [17] 0 0
Región Metro De Santiago
Country [18] 0 0
Chile
State/province [18] 0 0
Providencia, Santiago De Chile
Country [19] 0 0
Chile
State/province [19] 0 0
Santiago
Country [20] 0 0
Colombia
State/province [20] 0 0
Barranquilla
Country [21] 0 0
Colombia
State/province [21] 0 0
Bogota
Country [22] 0 0
Colombia
State/province [22] 0 0
Bogotá
Country [23] 0 0
Colombia
State/province [23] 0 0
Cali
Country [24] 0 0
Mexico
State/province [24] 0 0
Chihuahua
Country [25] 0 0
Mexico
State/province [25] 0 0
Jalisco
Country [26] 0 0
Mexico
State/province [26] 0 0
DF
Country [27] 0 0
Mexico
State/province [27] 0 0
Distrito Federal
Country [28] 0 0
Mexico
State/province [28] 0 0
Mexico City
Country [29] 0 0
Mexico
State/province [29] 0 0
Oaxaca
Country [30] 0 0
Peru
State/province [30] 0 0
Lima
Country [31] 0 0
Puerto Rico
State/province [31] 0 0
San Juan
Country [32] 0 0
Russian Federation
State/province [32] 0 0
Ekaterinburg
Country [33] 0 0
Russian Federation
State/province [33] 0 0
Irkutsk
Country [34] 0 0
Russian Federation
State/province [34] 0 0
Krasnodar
Country [35] 0 0
Russian Federation
State/province [35] 0 0
Moscow
Country [36] 0 0
Russian Federation
State/province [36] 0 0
St. Petersburg
Country [37] 0 0
South Africa
State/province [37] 0 0
Eastern Cape
Country [38] 0 0
South Africa
State/province [38] 0 0
Free State
Country [39] 0 0
South Africa
State/province [39] 0 0
Tembisa
Country [40] 0 0
South Africa
State/province [40] 0 0
Westdene
Country [41] 0 0
Taiwan
State/province [41] 0 0
Kaohsiung
Country [42] 0 0
Taiwan
State/province [42] 0 0
Taipei
Country [43] 0 0
Thailand
State/province [43] 0 0
Bangkok

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
ViiV Healthcare
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
GlaxoSmithKline
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) \[with or without ritonavir (RTV)\] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.
Trial website
https://clinicaltrials.gov/study/NCT02386098
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
ViiV Healthcare
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02386098